• Explore /
  • Poster
  • / The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.

The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.

Abstract Poster

Authors

Torben Hansen

T. Hansen

Danish Colorectal Cancer Group South, Vejle Hospital and University of Southern Denmark, Vejle, Denmark

T. Hansen , R. d. Christensen , R. F. Andersen , K. G. Spindler , A. Johnsson , A. K. M. Jakobsen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT00598156

Citation

J Clin Oncol 29: 2011 (suppl; abstr 3600)

Abstract #

3600

Poster Bd #

17H

Abstract Disclosures

Similar Posters

First Author: Kei Muro

First Author: Christophe Tournigand

First Author: Sun Young Kim

First Author: Masato Nakamura